Anthrax in the era of biowarfare;La maladie du charbon à l'heure du bioterrorisme

Presse Medicale

Volumn 32, Issue 4, 2003, Pages 167-173

  Bossi, Philippe ^a   Bricaire, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; DOXYCYCLINE; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G;

ADULT; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL MENINGITIS; BIOLOGICAL WARFARE; CHILD; CLINICAL FEATURE; DISEASE TRANSMISSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NONHUMAN; PRACTICE GUIDELINE; SKIN MANIFESTATION; TERRORISM;

ADULT; AMOXICILLIN; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BIOLOGICAL WARFARE; BIOTERRORISM; CHILD; CIPROFLOXACIN; DOXYCYCLINE; FEMALE; HUMANS; INFANT, NEWBORN; MALE; OFLOXACIN; PENICILLIN G; PENICILLINS; PREGNANCY; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 0037311034     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Center for Disease Control and Prevention. Use of anthrax vaccine in the United States; recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 4: RR-15.
2. Davies J. A major epidemic of anthrax in Zimbabwe. Cent Afr J Med 1982; 28: 291-8.
3. Center for Disease Control and Prevention. Recognition of illness associated with the intentional release of a biologic agent. MMWR 2001; 50: 893-7.
4. Maladie du charbon: www.afssaps.sante.fr.
5. Anthrax in www.iph.gov.be/epidemio/.
6. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm.
7. Bioterrorism alleging use of anthrax and interim guidelines for management-United States 1998. MMWR 1999; 48: 69-74.
8. Anthrax; Interim PHLS guidelines for action in the event of a deliberate release: www.phls.org.uk/facts/deliberate_releases.htm.
9. Inglesby T, O'Toole T, Henderson D et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287: 2236-52.
10. Protocol for dealing with suspected anthrax in Ireland. Dec 2001. www.doh.ie.
11. World Health Organization Health Aspect of Chemical and Biological Weapons. Geneva, Switzerland; 1970.
12. Meselson M, Guillemin J, Hugh-Jones M et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-8.
13. Jernigan J, Stephens D, Ashford D et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7: 933-44.
14. Center for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax-Connecticut, 2001. MMWR 2001; 50: 1077-9.
15. Suspected cutaneous anthrax in a laboratory worker-Texas 2002. MMWR 2002; 51: 179-81.
16. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341: 815-26.
17. Borio L, Frank D, Mani V et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 2001; 286: 2554-9.
18. Mina B, Dym JP, Kuepper F et al. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA 2002; 287: 858-62.
19. Barakat L, Quentzel H, Jernigan J et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287: 863-8.
20. Swartz M. Current concepts: recognition and management of anthrax-an update. N Engl J Med 2001; 345: 1621-6.
21. Pile J, Malone J, Eitzen E, Friedlander A. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158: 429-34.
22. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957; 73: 485-94.
23. Fritz D, Jaax N, Lawrence W et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995; 73: 691-702.
24. Glassman H. Industrial inhalation anthrax. Bacteriol Rev 1966; 30: 657-9.
25. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR 2001; 50: 941-8.
26. Sirisanthana T, Brown A. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002; 8: 649-51.
27. Tekin A, Bulut N, Unal T. Acute abdomen due to anthrax. Br J Surg 1997; 84: 813.
28. Bush L, Abrams B, Beall A, Johnson C. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345: 1607-10.
29. The European Agency for the Evaluation of Medicinal Products/CPMP guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. Feb 2002; www.emea.eu.int.
30. Bell D, Kozarsky P, Stephens D. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 2002; 8: 222-5.
31. Friedlander A, Welkos S, Pitt M et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167: 1239-43.
32. Friedlander A, Pittman P, Parker G. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282: 2104-6.
33. Schafazand S, Doyle R, Ruoss S, Weinacker A, Raffin T. Inhalational anthrax: epidemiology, diagnosis and management. Chest 1999; 116: 1369-76.
34. Bartlett J, Inglesby T, Borio L. Management of anthrax. Clin Infect Dis 2002; 35: 851-8.
35. Joellenbeck LM, Zwanziger LL, Durch JS and Strom BL (Editors) Committee to Assess the safety and efficacy of the anthrax vaccine, Medical Follow Up Agency. The Anthrax Vaccine. Is it safe? Does it work? Institute of Medicine, 2002.
36. www.camr.org.uk.